Novadoz Pharmaceuticals reported on Tuesday the receipt of the US FDA approval for the generic version of Pregabalin capsules in 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg strength capsules in 90 count bottles, with bulk sizes slated for post launch.
The patent expiration for the brand Lyrica, which is marketed by Pfizer, reportedly overlapped with the day Novadoz began shipping of the product.
According to Novadoz, Pregabalin is indicated for epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome as well as to treat epilepsy as adjunctive therapy for partial seizures.
Currently, the Lyrica brand is trending over USD5.4bn in published annual sales, added the company.
Novadoz Pharmaceuticals is the US based sales & marketing affiliate for MSN Labs, based in Hyderabad India, engaged in the development and manufacturing of API (active pharmaceutical ingredients), KSMs (key starting materials) and product intermediates.
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets
Newbury Pharmaceuticals secures approval for Macitentan in Denmark
Mallinckrodt and Endo to merge in USD6.7bn deal to create pharmaceutical leader
Genomma Lab Internacional announces quarterly dividend
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical